

BEST AVAILABLE COPY

AB

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :	A1	(11) International Publication Number: WO 97/47328 (43) International Publication Date: 18 December 1997 (18.12.97)
(21) International Application Number:	PCT/US97/09308	(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date:	12 June 1997 (12.06.97)	
(30) Priority Data:	08/662,656 13 June 1996 (13.06.96)	US
(71) Applicant:	NEURO IMAGING TECHNOLOGIES, LLC [US/US]; 1 Exeter Plaza, Boston, MA 02116 (US).	
(72) Inventors:	NEUMEYER, John, L.; 1 Holiday Road, Wayland, MA 01778 (US). TAMAGNAN, Gilles; 446 Old Connecticut Path #7, Framingham, MA 01701 (US). GAO, Yigong; 6 Tammie Road, Hopedale, MA 01747 (US).	
(74) Agents:	SCHURGIN, Stanley, M. et al.; Weingarten, Schurgin, Gagnebin & Hayes LLP, Ten Post Office Square, Boston, MA 02109 (US).	
(54) Title:	(SYNTHESIS OF FERROCENYL PHENYLTROPANE ANALOGS AND THEIR RADIO-TRANSFORMATION TO TECHNETIUM NEUROPROBES FOR MAPPING MONOAMINE REUPTAKE SITES)	
(57) Abstract	<p>Neuroprobes that include rhenium, manganese, and technetium for use in mapping monoamine reuptake sites are disclosed. Non-radioactive tricarbonylrheniumcyclopentadienyl (TRCp) or non-radioactive tricarbonylmanganese cyclopentadienyl (TMCp) phenyltropane analogs are synthesized for use as testing surrogates for radioactive technetium congeners. Ferrocenyl analogs of phenyltropane are disclosed as useful precursors for the preparation of novel tricarbonyltechnetiumcyclopentadienyl (TTCp) phenyltropane analogs in radioactive form.</p>	

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NB	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

- 1 -

SYNTHESIS OF FERROCENYL PHENYLTROPANE ANALOGS AND THEIR
RADIO-TRANSFORMATION TO TECHNETIUM NEUROPROBES FOR
MAPPING MONOAMINE REUPTAKE SITES

5

FIELD OF THE INVENTION

10

This invention relates to neuroprobes for mapping monoamine reuptake sites in the brain, and more particularly to neuroprobes incorporating rhenium or an isotope of rhenium, manganese or an isotope of manganese, or a radioisotope of technetium for mapping monoamine reuptake sites.

15

GOVERNMENT RIGHTS

Part of the work leading to this invention was made with United States Government support from SBIR Grant No. R44-MH49533 from the National Institutes of Health. Therefore, the U.S. Government has certain rights in this invention.

20

BACKGROUND OF THE INVENTION

25

A brain consists of a plurality of neurons that interact by exchanging chemical messengers. Each neuron generates neurochemicals, referred to as neurotransmitters, which act at receptor sites on the cellular membrane of a neuron. Receptors are associated with either ion channels through the cellular membrane or with secondary neurochemical messenger systems. By contrast, molecular complexes which transport chemicals across the cellular membrane of a neuron are referred to as reuptake sites. When a neurotransmitter has served its function, it is removed from the vicinity of the receptor by being bound to a reuptake site, which then transports the neurotransmitter to the interior of the neuron.

30

Just as there are many specialized neurons in the brain, there are also a variety of neurotransmitters, associated receptors, and reuptake sites. The major neurotransmitters, dopamine, norepinephrine, and serotonin, are referred to

35

- 2 -

collectively as the monoamine neurotransmitters.

A neuron can be classified according to the type of neurotransmitter that it uses to communicate with other neurons, with certain types of neurons being found predominantly in particular regions of the brain. For example, the striatal region of a mammalian brain is innervated by neurons using dopamine as a neurotransmitter. The striatum also contains a large number of non-dopaminergic neurons that have dopamine receptors. Certain compounds, such as cocaine and structurally related phenyltropanes, have a preferential affinity for dopamine reuptake sites, and therefore tend to bind to such sites. The effect of a molecule such as cocaine upon a dopamine reuptake site is to inhibit reuptake of the neurotransmitter dopamine, leaving more of the neurotransmitter available in the vicinity of the dopamine receptor.

In certain neurological diseases, distinct groups of neurons lose their normal physiological function. Consequently, the abnormal neurons may behave differently in the presence of some neurotransmitters and may also produce neurotransmitters in a manner that differs from a healthy neuron. For example, Parkinson's disease is caused by the degeneration of some of the dopaminergic neurons, which have a large number of dopamine reuptake sites, in the striatal region of the brain.

The localization of labelled neuroprobes can be used to find specialized neurons within particular regions of the brain. If the binding distribution of the labelled neuroprobe to its reuptake site is abnormal, it may indicate the presence of a neurological disease. Such an abnormal binding distribution can be observed by incorporating a radionuclide within molecules of the neuroprobe with a high binding affinity for the particular reuptake sites of interest. Then, an imaging technique can be used to obtain a representation of the in vivo spatial distribution of the reuptake sites.

- 3 -

5 Imaging techniques frequently used in diagnostic procedures include single photon emission computed tomography (SPECT) or Positron Emission Tomography (PET). The primary clinical interest in SPECT and PET agents specific for dopamine transporters (DA_T) at dopamine reuptake sites is in the diagnosis and staging of Parkinson's disease. It has been demonstrated with [¹²³I] (SPECT), [¹¹C] (PET), and [¹⁸F] (PET)-labelled phenyltropanes, a class of ligands which includes cocaine and has high affinity to the dopamine transporter, that the loss of dopamine transporters can be correlated with the severity of Parkinson's disease. However, [¹²³I], [¹¹C] and [¹⁸F] are expensive cyclotron-produced radionuclides and are not readily available for clinical applications, such as diagnostic procedures in a hospital.

10

15

In other applications of SPECT imaging, the most commonly used radionuclides are heavy metals, such as ^{99m}technetium. Technetium (Tc) in particular has by far the most desirable nuclear properties for diagnostic imaging. However, heavy metals are very difficult to incorporate into the molecular structure of neuroprobes because such probes are relatively small molecules (molecular weight less than 400). With the advent of commercial generator systems, instant technetium, innovations in chelation, and new chelating agents, there has been renewed interest in the use of ^{99m}Tc-labelled compounds. At the present time, chemical forms of ^{99m}Tc are the most widely used radiopharmaceuticals for radionuclide imaging of the brain, liver, lung and skeleton. The chemistry of ^{99m}Tc has proven difficult, however. This has resulted in the synthesis of few specific ^{99m}Tc-labelled probes.

20

25

30

The synthesis of a ^{99m}Tc-labelled tricarbonyltechnetiumcyclopentadiene or "cytectrene" complex bound to various substituents has been described (Kuntschke et al., J. Label. Cmpds. and Radiopharm. 36:193-203 (1995)). Several ^{99m}Tc chelates have also been attached to biologically

35


- 4 -

active molecules (Dizio et al., J. Nucl. Med. 33:558-569 (1992)). U.S. Pat. No. 5,104,638 to Nosco describes a method of making ^{99m}Tc-labelled compounds. Estrogens tagged with ^{99m}Tc-cytechtrene have also been prepared (Wenzel et al., J. Label. Comp. Radiopharm. 34:981-987 (1994)). Other syntheses of Tc-tagged biologically active molecules have been hampered by difficulties in the chemical procedures.

SUMMARY OF THE INVENTION

As the preferred radionuclide for use in a SPECT imaging study is ^{99m}Tc, the development of ^{99m}Tc-labelled phenyltropane analogues would provide a useful tool for routine clinical diagnosis of Parkinson's disease. This need is met by the present invention which is directed to tricarbonyltechnetiumcyclopentadienyl (TTCp) phenyltropane analogs and their preparation in radioactive form from novel ferrocenyl precursors. Novel tricarbonylrheniumcyclopentadienyl (TRCp) or tricarbonylmanganese cyclopentadienyl (TMCp) phenyltropane analogs are also featured for use as surrogates for radioactive technetium congeners. Useful TTCp-tagged phenyltropane analogues can be determined by evaluating their TMCp or TRCp surrogates without involving radiochemistry.

In one embodiment, the invention features a neuroprobe for mapping monoamine reuptake sites, the neuroprobe having the formula:



wherein X = F, Cl, Br, I, H or alkyl; X' = F, Cl, Br, I, H or alkyl; R = alkyl, halogen substituted alkyl, cycloalkyl, halogen substituted cycloalkyl, alkenyl, halogen substituted


- 5 -

alkenyl, aryl or halogen substituted aryl; and R' = -(CH₂)_nY,
wherein

Y = -O-C(O)-Z, -C(O)-Z, or -NR"-C(O)-Z; and n=1-6;

and wherein further R" = alkyl, cycloalkyl or H;

5 and Z =




10

wherein M = rhenium or an isotope of rhenium,
manganese or an isotope of manganese, or an isotope of
15 technetium.

In another embodiment, the invention features a neuroprobe for mapping monoamine reuptake sites, the neuroprobe having the formula:

20




25

wherein X = F, Cl, Br, I, H or alkyl; X' = F, Cl, Br, I, H or alkyl; R' = alkyl, halogen substituted alkyl, cycloalkyl, halogen substituted cycloalkyl, alkenyl, halogen substituted alkenyl, aryl or halogen substituted aryl; and
30 R = -(CH₂)_nY, wherein Y = -O-C(O)-Z, -C(O)-Z, or -NR"-C(O)-Z; and n=1-6;

- 6 -

and wherein further R" = alkyl, cycloalkyl or H;
and Z =

5




wherein M = rhenium or an isotope of rhenium,
10 manganese or an isotope of manganese, or an isotope of
technetium.

In another embodiment, the invention features a neuroprobe for mapping monoamine reuptake sites, the neuroprobe having the formula:

15

20




25

wherein X = F, Cl, Br, I, H or alkyl; X' = F, Cl, Br, I, H or alkyl; R' = alkyl, halogen substituted alkyl, cycloalkyl, halogen substituted cycloalkyl, alkenyl, halogen substituted alkenyl, aryl or halogen substituted aryl; and R = -(CH₂)_nY, wherein Y = -O-C(O)-Z, -C(O)-Z, or -NR"-C(O)-Z; and n=1-6;

- 7 -

and wherein further R" = alkyl, cycloalkyl or H;
 and Z =


5



10 wherein M = rhenium or an isotope of rhenium, manganese or an isotope of manganese, or an isotope of technetium.

15 The invention also features precursors for the preparation of tricarbonyltechnetiumcyclopentadienyl (TTCp) phenyltropane analogs. In one embodiment, the precursors are of the formula

20



25


wherein X = F, Cl, Br, I, H or alkyl; X' = F, Cl, Br, I, H or alkyl; R = alkyl, halogen substituted alkyl, cycloalkyl, halogen substituted cycloalkyl, alkenyl, halogen substituted alkenyl, aryl or halogen substituted aryl; and R' = -(CH₂)_nY, wherein

Y = -O-C(O)-Z, -C(O)-Z, or -NR"-C(O)-Z; and n=1-6;

- 8 -

and wherein further R" = alkyl, cycloalkyl or H;
and Z =


5



10

or


15



20

In another embodiment, the precursors are of the formula:

25



30

wherein X = F, Cl, Br, I, H or alkyl; X' = F, Cl, Br, I, H or alkyl; R' = alkyl, halogen substituted alkyl, cycloalkyl, halogen substituted cycloalkyl, alkenyl, halogen substituted alkenyl, aryl or halogen substituted aryl; and R = -(CH₂)_nY, wherein Y = -O-C(O)-Z, -C(O)-Z, or -NR"-C(O)-Z; and n=1-6;


35

and wherein further R" = alkyl, cycloalkyl or H;

- 9 -

and Z =


5



10


or

15



20 In another embodiment, the precursors are of the
formula:


25




30 wherein X = F, Cl, Br, I, H or alkyl; X' = F, Cl, Br, I,
H or alkyl; R' = alkyl, halogen substituted alkyl,
cycloalkyl, halogen substituted cycloalkyl, alkenyl, halogen
substituted alkenyl, aryl or halogen substituted aryl; and
R = -(CH₂)_nY, wherein Y = -O-C(O)-Z, -C(O)-Z, or -NR"-C(O)-Z;
and n=1-6;

35 and wherein further R" = alkyl, cycloalkyl or H;
and Z =

- 10 -



or



15

The ferrocenyl derivatives described above react readily
20 with $^{99m}\text{TcO}_4^-$ and a carbonyl donor ($\text{M}(\text{CO})_5\text{Br}$, M = metal such as Cr or Mn) at 130-150°C to transform to radiolabelled $[^{99m}\text{Tc}]$ -tricarbonyltechnetiumcyclopentadienyl analogs, which are useful for mapping monoamine transporters. Preferably, the X and X' substituents are located in the meta or para positions.
25

Certain factors must be taken into consideration when radiopharmaceuticals are prepared. An important factor is the time frame during which a radiopharmaceutical must maintain its integrity. When evaluating pharmacokinetics or diagnosing a patient, a medical tracer must remain stable in vivo for the duration of the study to be performed. Analogs incorporating ^{99m}Tc benefit from a short half-life (approx. 6 hours), which reduces the total radiation dose to the patient. ^{99m}Tc is also easily detected by a gamma-ray camera due to the emission of a 140 keV photon.
30
35

- 11 -

DESCRIPTION OF THE DRAWING

The invention will be more fully understood from the following detailed description taken in conjunction with the accompanying drawings in which:

5 Fig. 1 is a diagram of the synthetic steps in preparing a compound of the invention;

Fig. 2 is another diagram of a series of synthetic steps for preparing another compound of the invention;

10 Fig. 3 is another diagram of a series of synthetic steps for preparing compounds of the invention;

Fig. 4 is another diagram of a series of synthetic steps for preparing another compound of the invention;

Fig. 5 is another diagram of a series of synthetic steps for preparing another compound of the invention; and

15 Fig. 6 is a diagram of a series of synthetic steps to produce [^{99m}Tc]-labelled compounds of the invention.

DETAILED DESCRIPTION OF THE INVENTION

20 The examples which follow describe methods for preparing tricarbonylrheniumcyclopentadienyl (TRCp) or tricarbonylmanganese cyclopentadienyl (TM Cp)-tagged phenyltropane analogs. Methods are also described for preparing novel ferrrocenyl precursors of tricarbonyltechnetiumcyclopentadienyl (TTCp)-tagged phenyltropane analogs and their transformation to TTCp compounds labelled with ^{99m}Tc for use in biological systems.

EXAMPLE I

Preparation of 3 β -(4-iodophenyl)-2 β -(tricarbonylrhenium-cyclopentadienylcarboxymethyl)tropane (RBI-211)

A. Synthesis of 2 β -hydroxymethyl-3 β -(4-iodophenyl)-tropane-D-Tartrate

35 As shown in Fig. 1, 5 mmol 3 β -(4-iodophenyl)-2 β -(carbomethoxy)tropane (β -CIT (1)) is dissolved in 25 ml ethyl ether at 0°C, and 2 equivalents of lithium borohydride (LiBH₄) are added. The temperature is raised to room

- 12 -

temperature, and stirring is continued for approximately 2 hr. The reaction is quenched with water and the aqueous phase of the mixture is extracted with methylene chloride. The organic phase is collected and dried over magnesium sulfate and the solvent is removed to give 2 β -hydroxymethyl-3 β -(4-iodophenyl)

5 tropane free base (2) in quantitative yield. 2 β -hydroxymethyl-3 β -(4-iodophenyl)tropane was fully characterized as D-tartaric acid: mp= 90-92°C, [α]D²⁰-66.3° (c, 0.525, MeOH). ¹H NMR (250 MHz, CDCl₃): δ 7.59 (d, J= 8.4 Hz, 2H); 6.99 (d, J= 8.4 Hz, 2H); 3.76 (dd, J = 11.06 Hz; 1H); 3.44 (d, J = 4.59 Hz, 1H); 3.32 (m, 2H); 3.01 (m, 1H); 2.47 (td; J = 2.88 Hz, J = 12.74 Hz; 1H); 2.20 (s, 3H); 2.16 (m, 2H); 1.70 (m, 2H); 1.65 (m, 1H); 1.46 (m, 1H). Anal. (C₁₅H₂₀NOI) (C₄H₆O₆): CHN.

B. Synthesis of 3 β -(4-iodophenyl)-2 β -(tricarbonylrhenium-cyclopentadienylcarboxymethyl)tropane, RBI-211 (3)

20 The product prepared in step A above (compound 2) is dissolved in toluene (1 g/10 ml) and 1.1 equiv. of triethylamine and 1.1 equiv. of cyclopentadienylcarbonyl chloride tricarbonylrhenium are added under nitrogen. After heating at reflux for 30 min., the solvent is removed and the residue is passed through a silica gel column equilibrated with hexane/ether/triethanolamine (50/50/5) to produce 3 β -(4-iodophenyl)-2 β -(tricarbonylrhenium-cyclopentadienylcarboxymethyl)tropane (3) (RBI-211) in 76% yield. mp: 161-162°C; ¹H NMR (250 MHz, CDCl₃): δ 7.59 (d, J = 8.4 Hz, 2H); 6.99 (d, J = 8.4 Hz, 2H); 5.80 (m, 1H); 5.62 (m, 1H); 5.30 (m, 2H); 4.48 (dd, J = 7.57 Hz, J = 11.03 Hz; 1H); 53.86 (dd; J = 5.86 Hz; J = 10.93 Hz, 1H); 3.26 (m, 1H); 3.20 (m, 1H); 3.07 (m, 1H); 2.22 (s; 3H); 2.10 (m, 3H); 1.61 (m, 3H). MS (FAB): 720 (29%); 718 (23%); 340 (100%). Anal. (C₂₄H₂₃NO₅IRe): CHN.

- 13 -

EXAMPLE 2

Preparation of 1,1'-bis-[3 β -(4-iodophenyl)tropan-2 β -ylmethoxycarbonyl] ferrocene (5)

As shown in Fig. 2, to a solution of 2 β -hydroxymethyl-3 β -(4-iodophenyl)tropane (1) in toluene (1 g/10 mL), 1.1 equiv. of triethylamine and 0.5 equiv. of 1,1'-ferrocenedicarbonyl chloride (4) are added under nitrogen. After heating at reflux for 30 min. the solvent is removed, and the residue passed through a silica gel column with hexane/ether/TEA: 50/50/5 to give 1,1'-bis-[3 β -(4-iodophenyl)tropan-2 β -ylmethoxycarbonyl] ferrocene (5) in 82% yield. mp: 74-75°C. 1 H NMR (250 MHz, CDCl₃): δ 7.59 (d, J = 8.4 Hz, 4H); 6.99 (d, J = 8.4 Hz, 4H); 4.57 (s, 4H); 4.36 (m, 6H); 3.85 (m, 2H); 3.30 (m, 4H); 3.06 (m, 2H); 2.29 (s, 6H; 2.17 (m, 8H); 1.68 (m, 2H). Anal. (C₄₂H₄₆FeNO₄I₂Re): CHN.

EXAMPLE 3

Preparation of N-(tricarbonylrheniumcyclopentadienylbutan-1-one-4-yl)-2 β -carbomethoxy-3 β -(4-chlorophenyl)nortropane, RBI-235 (8)

As shown in Fig. 3, 4-bromobutan-1-one-cyclopentadiene tricarbonylrhenium (6) (0.4 mmol) and KI (10 mg) are added to a solution of nor- β -CCT (7) (0.27 mmol) and triethylamine (TEA, 46 mmol) in toluene (10 mL). The mixture is refluxed under nitrogen for 3 hours and the progress of the reaction is monitored with thin layer chromatography (TLC). The solvent is removed under reduced pressure and the residue is passed through a silica gel column (equilibrated with a mixture of hexane/ether/triethylamine: 50/50/5) to give N-(tricarbonylrheniumcyclopentadienylbutan-1-one-4-yl)-2 β -carbomethoxy-3 β -(4-chlorophenyl)nortropane (8) (RBI-235) in 64% yield, as a brown oil. Anal. (C₂₇H₂₂NO₆ClRe)₂(H₂O): CHN 1 H NMR: (250 MHz CDCl₃): δ 7.19 (dd, J = 7.15 Hz, J = 7.62 Hz, 4H); 6.11 (s, 1H); 5.05 (s, 1H); 5.39 (m, 2H); 3.69 (m, 1H); 3.49 (m, 5H); 3.36 (m, 1H); 2.89 (m, 3H); 2.62 (m, 1H); 2.29

- 14 -

(m, 2H); 2.05 (m, 1H); 1.71 (m, 3H); 1.21 (m, 2H).

EXAMPLE 4

Preparation of N-(tricarbonylmanganese)cyclopentadienylbutan-1-one-4-yl)-2β-carbomethoxy-3β-(4-chlorophenyl)nortropane, RBI-233 (10)

As shown in Fig. 3, N-(tricarbonylmanganese)cyclopentadienylbutan-1-one-4-yl)-2β-carbomethoxy-3β-(4-chlorophenyl)nortropane (10) is prepared using similar procedures as described in Example 3. 4-Bromobutan-1-one-cyclopentadienetricarbonyl manganese (9) (0.4 mmol) and KI (10 mg) are added to a solution of nor- β -CCT (7) (0.27 mmol) and triethylamine (TEA, 46 mmol) in toluene (10 mL). The mixture is refluxed under nitrogen for 3 hours and the progress of the reaction is monitored with thin layer chromatography (TLC). The solvent is removed under reduced pressure and the residue is passed through a silica gel column (equilibrated with a mixture of hexane/ether/triethylamine: 50/50/5) to give N-(tricarbonylmanganese)cyclopentadienylbutan-1-one-4-yl)-2β-carbomethoxy-3β-(4-chlorophenyl)nortropane (10) (RBI-233) in 64% yield, as an oil. Anal. ($C_{27}H_{27}NO_6ClMn$)₃(H_2O)₂:CHN. 1H NMR (250 MHz, CDCl₃): δ 7.21 (m, 4H); 4.84 (s, 2H); 3.69 (br, 1H); 3.49 (br, 3H); 3.36 (br, 1H); 2.90 (m, 2H); 2.80 (m, 1H); 2.61 (m, 2H); 2.27 (m, 2H); 2.03 (m, 2H); 1.71 (m, 4H); 1.22 (m, 1H).

EXAMPLE 5

Preparation of N-(tricarbonylrhenium)cyclopentadienylcarboxy-propyl)-2β-carbomethoxy-3β-(4-chlorophenyl)nortropane (RBI-232) (13)

As shown in Fig. 4, to a solution of N-(2-hydroxypropyl)-2β-carbomethoxy-3β-(4-chlorophenyl)tropane (11) in toluene (1g/10ml) is added 1.1 equiv. of triethylamine (TEA) and 1.1 equiv. of cyclopentadienecarbonyl chloride tricarbonylrhenium (12) under nitrogen. After heating at reflux for 30 min., the solvent is removed and the

- 15 -

residue passed through a silica gel column with hexane/ether/TEA: 50/50/5 to give N-(tricarbonylrheniumcyclopentadienylcarboxypropyl)-2 β -carbomethoxy-3 β -(4-chlorophenyl) nortropane (13) (RBI-232) in 45% yield. ^1H NMR (250 MHz, CDCl₃) : Δ 7.26 (m, 4H); 6.01 (m, 2H); 5.36 (m, 2H); 4.31 (m, 2H); 3.67 (br, 1H); 3.47 (s, 3H); 3.36 (m, 1H); 2.90 (m, 2H); 2.51 (m, 2H); 2.35 (m, 2H); 2.10 (m, 2H); 1.71 (m, 4H). Anal. (C₂₇H₂₇NO₂ClRe) (H₂O)₃ CHN

10

EXAMPLE 6

Preparation of 3 β -(4-Chlorophenyl)-2 β -tricarbonylrhenium-cyclopentadienylcarboxymethyl)tropane, RBI-219 (15)

As shown in Fig. 5, a solution of N-(2-hydroxypropyl)-2 β -hydroxymethyl-3 β -(4-chlorophenyl)tropane (14) in toluene (1g/10ml) is combined with 1.1 equiv. of triethylamine and 1.1 equiv. of cyclopentadienecarbonylchloride tricarbonylrhenium (12) under nitrogen. After heating at reflux for 30 min., the solvent is removed and the residue passed through a silica gel column equilibrated with hexane/ether/TEA (50/50/5) to give 3 β -(4-chlorophenyl)-2 β -tricarbonylrheniumcyclopentadienyl-carboxymethyl)tropane (15) (RBI-219) in 81% yield. mp = 149-150°C. ^1H NMR (250 MHz, CDCl₃): Δ 7.26 (d, J=8.1 Hz, 2H); 7.14 (d, J=8.1 Hz, 2H); 5.82 (m, 1H); 5.66 (m, 1H); 5.33 (m, 2H); 4.48 (dd, J=7.57 Hz, J=11.03 Hz; 1H); 3.86 (dd; J=10.93 Hz, 1H); 3.26 (m, 1H); 3.20 (m, 1H); 3.07 (m, 1H); 2.22 (s; 3H); 1.61 (m, 3H). Anal. (C₂₄H₂₃NO₅ClRe): CHN

30

Procedure for $^{99\text{m}}\text{Tc}$ Radiolabeling

Radiolabeling of ferrocenyl precursors can be carried out using standard procedures known in the art (see Wenzel et al., J. Label. Comp. Radiopharm. 31, 641-650 (1992); Wenzel et al., J. Label. Comp. Radiopharm. 34, 981-987 (1994)).

In one embodiment shown in Fig. 6, a ferrocene compound such as 1,1'-bis-[3 β -(4-iodophenyl)tropan-2 β -

- 16 -

ylmethoxycarbonyl] ferrocene from Example 2 above (5) (2 mg) and Mn(CO)₅Br are mixed in equimolar ratios in THF, methanol or DMF in a test tube. An equivalent amount of ^{99m}TcO₄⁻ eluate (0.5-10 mCi, eluted from a technetium-99m generator) is added. The tube is sealed and heated to 150°C for 1 h, after which the reaction mixture is purified by semipreparative HPLC (RP-18), and eluted with 0.5 mL H₂O and 0.5 mL methanol to isolate the [^{99m}Tc]-labelled compound, and to remove insoluble black particles and unwanted ^{99m}TcO₂. Other related ferrocene compounds may also be labelled with ^{99m}Tc using similar procedures known in the art in combination with the skills of the ordinary skilled practitioner.

Binding Assays for Candidate Compounds

Each of the compounds synthesized above may be tested for binding to various reuptake sites found in homogenates of brain tissue. Each compound is mixed with a crude membrane fraction of homogenates of rat brain corpus striatum (for the dopamine transporter) or frontoparietal cerebral cortex (for the serotonin and norepinephrine transporters). Each compound is tested at six concentrations and in duplicate. Each mixture is incubated in Tris buffer (pH 7.4) containing Na^+ (120 nM), following previously reported methods as described in, e.g., Neumeyer et al., J. Med. Chem. 37:1558-1561 (1994); Anderson, J. Neurochem. 48:1887-1896 (1987); Kula et al., Neuropharmacol. 30:89-92 (1991); Habert et al., Eur. J. Pharmacol. 118:107-114 (1985); and Tejani-Butt, J. Pharmacol. Exp. Ther. 260:427-436 (1992). For the dopamine transporter assay, the radioligand was [^3H]GBR-12935 (13 Ci/mmol; $K_d = 1.0$ nM) at a test concentration (L) = 0.4 nM (for 45 min at 4°C), with or without 30 μM methylphenidate used to define nonspecific binding (blank). For the serotonin transporter assay, $L = 0.2$ nM [^3H]paroxetine (20 Ci/mmol; $K_d = 0.15$ nM [^3H]paroxetine (20 Ci/mmol; $K_d = 0.15$ nM (for 60 min at 20°C); and 1 μM fluoxetine (Lilly Labs., Indianapolis, IN) as the blank

- 17 -

5

agent. For the norepinephrine transporter assay, L = 0.8 nM [³H]nisoxetine (50 Ci/mmol; Kd = 0.8 nM (for 180 min at 4°C); and 2 μ M desipramine (Marion Merrel Dow, Kansas City, MO) as the blank agent. All radioligands were from DuPont-NEN, Boston, MA. Concentration-inhibition curves were computer-fit to determine IC₅₀ \pm SEM, and converted to K_i values from the relationship K_i = IC₅₀/(1 + [L/Kd]).

10

To evaluate the binding affinities and selectivity of TRCp-tagged phenyltropane analogs for the monoamine transporters, initially, the TRCp or TMCp surrogates were prepared to test their ability to selectively bind to desired transporters in radioreceptor assays using the above-described procedure. The resulting affinities and selectivity of the compounds on transporter sites are comparable to the affinity value of β -CIT used as a reference standard to establish the design of targeted ferrocenyl precursors for ^{99m}Tc-radiolabeling.

15

TRCp and TMCp-tagged phenyltropane analogs were evaluated using the above-described radioreceptor binding assay. The results are illustrated in TABLE 1 and compared to results with β -CIT. In TABLE 1, selectivity is defined as the ratio of K_i for the dopamine transporter to the K_i for the serotonin transporter.

25

TABLE 1
Affinity of β -CIT analogs for the
dopamine and serotonin transporter

Compound	Dopamine Transporter (DA _T) (K _i , nM)	Serotonin Transporter (5-HT _T) (K _i , nM)	DA _T /5-HT _T Selectivity
RBI-211	7.22 \pm 1.06	34.6 \pm 3.4	0.21
RBI-219	4.41 \pm 0.76	11.9 \pm 1.7	0.37
RBI-232	2.66 \pm 0.33	0.56 \pm 0.08	4.75
RBI-233	1.67 \pm 0.39	0.84 \pm 0.06	2
RBI-235	1.29 \pm 0.1	0.37 \pm 0.04	3.49
β -CIT	1.40 \pm 0.2	0.46 \pm 0.06	3.04

- 18 -

Although the invention has been shown and described with respect to an illustrative embodiment thereof, it should be appreciated that the foregoing and various other changes, omissions, and additions in the form and detail thereof may 5 be made without departing from the spirit and scope of the invention as delineated in the claims.

- 19 -


CLAIMS

What is claimed is:

1. A neuroprobe for mapping monoamine reuptake sites, the neuroprobe having the formula:

5

10



wherein:

X = F, Cl, Br, I, H or alkyl;

15


X' = F, Cl, Br, I, H or alkyl;

R = alkyl, halogen substituted alkyl, cycloalkyl, halogen substituted cycloalkyl, alkenyl, halogen substituted alkenyl, aryl or halogen substituted aryl; and

20

R' = -(CH₂)_nY, wherein Y = -O-C(O)-Z, -C(O)-Z, or -NR"-C(O)-Z; and n=1-6; and wherein further R" = alkyl, cycloalkyl or H; and Z =

25



wherein M = rhenium or an isotope of rhenium, manganese or an isotope of manganese, or an isotope of technetium.

30

2. The neuroprobe of claim 1, wherein X is in the meta or para position.


35

3. The neuroprobe of claim 1, wherein X' is in the meta or para position.

- 20 -

4. The neuroprobe of claim 1, wherein said isotope of Tc is 99m Tc.

5. A neuroprobe for mapping monoamine reuptake sites, the neuroprobe having the formula:




wherein:

X = F, Cl, Br, I, H or alkyl;

X' = F, Cl, Br, I, H or alkyl;

R' = alkyl, halogen substituted alkyl, cycloalkyl, halogen substituted cycloalkyl, alkenyl, halogen substituted alkenyl, aryl or halogen substituted aryl; and

R = -(CH₂)_nY, wherein Y = -O-C(O)-Z, -C(O)-Z, or -NR"-C(O)-Z; and n=1-6; and wherein further R" = alkyl, cycloalkyl or H; and Z =



25

30

wherein M = rhenium or an isotope of rhenium, manganese or an isotope of manganese, or an isotope of technetium.

35

6. The neuroprobe of claim 5, wherein X is in the meta or para position.

- 21 -


7. The neuroprobe of claim 5, wherein X' is in the meta or para position.

5 8. The neuroprobe of claim 5, wherein said isotope of Tc is ^{99m}Tc .

9. A neuroprobe for mapping monoamine reuptake sites, the neuroprobe having the formula:

10

15



wherein:


X = F, Cl, Br, I, H or alkyl;

X' = F, Cl, Br, I, H or alkyl;

20 R' = alkyl, halogen substituted alkyl, cycloalkyl, halogen substituted cycloalkyl, alkenyl, halogen substituted alkenyl, aryl or halogen substituted aryl; and

R = $-(\text{CH}_2)_n\text{Y}$, wherein Y = $-\text{O}-\text{C}(\text{O})-\text{Z}$, $-\text{C}(\text{O})-\text{Z}$, or $-\text{NR}''-\text{C}(\text{O})-\text{Z}$; and n=1-6; and wherein further R'' = alkyl, cycloalkyl or H; and Z =

25



30

wherein M = rhenium or an isotope of rhenium, manganese or an isotope of manganese, or an isotope of technetium.

35


10. The neuroprobe of claim 9, wherein X is in the meta or para position.

- 22 -

11. The neuroprobe of claim 9, wherein X' is in the meta or para position.

12. The neuroprobe of claim 9, wherein said isotope of Tc
5 is ^{99m}Tc .

13. A compound of the formula:



15

wherein:

X = F, Cl, Br, I, H or alkyl;


X' = F, Cl, Br, I, H or alkyl;

20

R = alkyl, halogen substituted alkyl, cycloalkyl, halogen substituted cycloalkyl, alkenyl, halogen substituted alkenyl, aryl or halogen substituted aryl; and

R' = $-(\text{CH}_2)_n\text{Y}$, wherein Y = $-\text{O}-\text{C}(\text{O})-\text{Z}$, $-\text{C}(\text{O})-\text{Z}$, or $-\text{NR}''-\text{C}(\text{O})-\text{Z}$; and n=1-6; and wherein further R'' = alkyl, cycloalkyl or H; and Z =

25




30

or

35

- 23 -

5




10 14. The neuroprobe of claim 13, wherein X is in the meta or para position.

15. The neuroprobe of claim 13, wherein X' is in the meta or para position.

16. The neuroprobe of claim 13, wherein said isotope of Tc is ^{99m}Tc .

17. A compound of the formula:

20



25

wherein:

X = F, Cl, Br, I, H or alkyl;


X' = F, Cl, Br, I, H or alkyl;

30 R' = alkyl, halogen substituted alkyl, cycloalkyl, halogen substituted cycloalkyl, alkenyl, halogen substituted alkenyl, aryl or halogen substituted aryl; and


R = $-(\text{CH}_2)_n\text{Y}$, wherein Y = $-\text{O}-\text{C}(\text{O})-\text{Z}$, $-\text{C}(\text{O})-\text{Z}$, or $-\text{NR}''-\text{C}(\text{O})-\text{Z}$; and n=1-6; and wherein further R'' = alkyl, cycloalkyl or H; and Z =

35

- 24 -



or




15

18. The neuroprobe of claim 17, wherein X is in the meta or
20 para position.

19. The neuroprobe of claim 17, wherein X' is in the meta or para position.

25 20. The neuroprobe of claim 17, wherein said isotope of Tc is ^{99m}Tc .

21. A compound of the formula:



35

wherein:

- 25 -


X = F, Cl, Br, I, H or alkyl;

X' = F, Cl, Br, I, H or alkyl;

R' = alkyl, halogen substituted alkyl, cycloalkyl,
halogen substituted cycloalkyl, alkenyl, halogen substituted
5 alkenyl, aryl or halogen substituted aryl; and

R = -(CH₂)_nY, wherein Y = -O-C(O)-Z, -C(O)-Z, or -NR"-
C(O)-Z; and n=1-6; and wherein further R" = alkyl, cycloalkyl
or H; and Z =


10



15

20

or



25


22. The neuroprobe of claim 21, wherein X is in the meta or
30 para position.

23. The neuroprobe of claim 21, wherein X' is in the meta or para position.

- 26 -

24. The neuroprobe of claim 21, wherein said isotope of Tc is ^{99m}Tc .

1/5



2/5





FIG. 2



4/5




FIG. 4




FIG. 5

5/5





FIG. 6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/09308

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 51/00; A61M 36/14

US CL : 424/1.85

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/1.11, 1.37, 1.65, 1.85; 546/4, 10, 124, 125, 128, 132; 534/10-16

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

aps, medline, biosis, caplus, uspatful, embase


C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ARSON, B. et al. Synthesis and Ligand Binding of η^6 -(2 β -carbomethoxy-3 β -phenyltropone) Transition Metal Complexes. J. Med. Chem. 1996, Vol. 39, No. 7, pages 1560-1563, especially, page 1561, Scheme 1.	1-24

Further documents are listed in the continuation of Box C.

See patent family annex.

• Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance		
"E" earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"Z"	document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
05 AUGUST 1997	29 AUG 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer Dameron Jones  Telephone No. (703) 308-1235